ArticleJournal of virology2025
Anti-pA137R antibodies exacerbate the pathogenicity of African swine fever virus in pigs.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Towards an Original Anti-ASFV Vaccine: Cellular Immunity Induced by Extracellular Vesicles Engineered with ASFV Proteins.Vaccines · 2026Article
- ASFV pA137R protein triggers inflammatory response by inducing NF-κB signaling pathway and facilitating NLRP3 inflammasome assembly.Virologica Sinica · 2026Article
- Article
- ASFV Proteins Presented at the Surface of T7 Phages Induce Strong Antibody Responses and Immune Cell Proliferation inVaccines · 2025Article
- Antibody-Dependent Cellular Cytotoxicity Elicited by the Antibodies Against the E120R Protein of African Swine Fever Virus.Vaccines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever virus (ASFV) is the causative agent of African swine fever (ASF), a highly contagious disease with a mortality of up to 100% in pigs. Currently, no safe and effective vaccines are available globally, except for two licensed vaccines in Vietnam. One of the factors impeding the development of vaccines is antibody-dependent enhancement (ADE). Our previous study showed that the antibodies against the ASFV protein A137R (pA137R) could promote ADE of ASFV infection in primary porcine alveolar macrophages. However, direct evidence of ADE in target animals remains limited. Here, we investigated whether anti-pA137R antibodies exacerbate ASFV pathogenicity in pigs. The immunization-challenge experiment showed that the pigs immunized with pA137R exhibited more severe clinical signs and died earlier than the unimmunized ones. Meanwhile, the examination of viral replication in the blood and various tissues revealed that the anti-pA137R antibodies promoted the infectivity of ASFV. Notably, the production of interferon alpha was significantly upregulated in the blood of the immunized piglets, while the level of interferon beta, tumor necrosis factor alpha, and interleukin 1beta remained unchanged. Mechanistically, the Fc gamma receptor (Fc
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.